WO2004074502A2 - A process of preparing imatinib - Google Patents

A process of preparing imatinib Download PDF

Info

Publication number
WO2004074502A2
WO2004074502A2 PCT/GB2004/000018 GB2004000018W WO2004074502A2 WO 2004074502 A2 WO2004074502 A2 WO 2004074502A2 GB 2004000018 W GB2004000018 W GB 2004000018W WO 2004074502 A2 WO2004074502 A2 WO 2004074502A2
Authority
WO
WIPO (PCT)
Prior art keywords
imatinib
formula
methyl
salt
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/000018
Other languages
French (fr)
Other versions
WO2004074502A3 (en
Inventor
Rajendra Narayanrao Kankan
Dharmaraj Ramachandra Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to BRPI0407672-9A priority Critical patent/BRPI0407672A/en
Priority to NZ542040A priority patent/NZ542040A/en
Priority to KR1020057015166A priority patent/KR101086845B1/en
Priority to JP2006502181A priority patent/JP5064024B2/en
Priority to AU2004213616A priority patent/AU2004213616B2/en
Priority to EP04700728A priority patent/EP1599462B1/en
Priority to CA2516370A priority patent/CA2516370C/en
Priority to US10/546,193 priority patent/US7638627B2/en
Publication of WO2004074502A2 publication Critical patent/WO2004074502A2/en
Publication of WO2004074502A3 publication Critical patent/WO2004074502A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present invention is concerned with a process of preparing imatinib, either as the free base or as acid addition salts thereof, and also such imatinib free base and imatinib acid addition salts prepared by the process ofthe present invention.
  • Imatinib is the international non-proprietary name for N- ⁇ 5-[4-(4-methyl piperazine methyl)- benzoylamido]-2-methylphenyl ⁇ -4-(3-pyridyl)-2-pyrimidine amine.
  • EP 0564409 describes the preparation of imatinib and the use thereof, especially as an anti- tumour agent.
  • Example 21 describes the preparation of imatinib free base.
  • WO 99/03854 describes preparation of imatinib mesylate from imatinib free base, the preparation of the latter being referred to above mentioned EP 0564409.
  • the reduction reaction is usually carried out in presence of palladium catalyst under hydrogenation conditions.
  • the condensation is carried out in presence of a base, such as pyridine, triethylamine or the like.
  • the benzoyl chloride of formula (Ilia) is usually obtained as the dihydrochloride and used as such for the amidation step, and further an equivalent of hydrochloric acid is released during the reaction of N-(2- methyl-5-aminophenyl-4-(3-pyridyl)-2- ⁇ yrimidine amine of formula (II) with the benzoyl chloride of formula (Ilia).
  • a specific hydrochloride salt of imatinib of formula (I) prepared according to the present invention is imatinib trihydrochloride monohydrate.
  • a process of preparing imatinib either as the free base or as an acid addition salt, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with 4-(4-methyl-piperazino methyl)benzoyl chloride of formula (Ilia)
  • an imatinib hydrohalide salt which is a hydrochloride salt of imatinib of formula (la) where n represents 1, 2 or 3, either in anhydrous or hydrated form, which can as desired optionally be further converted either to the free base or a further acid addition salt.
  • a specific hydrochloride salt of imatinib of formula (la) prepared according to the present invention is imatinib trihydrochloride monohydrate.
  • hydrohalide salt of imatinib of formula (I) either in anhydrous or hydrated form (nHHal)
  • n 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo, in particular where the imatinib hydrohalide salt of formula (I) is a hydrobromide or hydrochloride salt of imatinib.
  • the present invention provides a hydrochloride salt of imatinib of formula (la) either in anhydrous or hydrated form
  • n 1, 2 or 3.
  • a specific hydrochloride salt of imatinib prepared according to the present invention is imatinib trihydrochloride monohydrate.
  • the present invention also provides a hydrohalide salt of imatinib of formula (I) either in anhydrous or hydrated form obtained by a process substantially as hereinbefore described
  • nHHal where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo, in particular where the imatinib hydrohalide salt of formula (I) is a hydrobromide or hydrochloride salt of imatinib
  • the present invention provides a hydrochloride salt of imatinib of formula (la) either in anhydrous or hydrated form (especially imatinib trihydrochloride monohydrate) obtained by a process substantially as hereinbefore described
  • n 1, 2 or 3.
  • a hydrohalide salt of imatinib of formula (I), in particular a hydrobromide or hydrochloride salt of imatinib, and especially a hydrochloride salt of imatinib of formula (la), substantially as hereinbefore described can be employed as an intermediate in the preparation of imatinib free base or a further acid addition salt of imatinib, such as imatinib mesylate substantially as hereinafter described in greater detail.
  • inert organic solvent an organic solvent, which under the reaction conditions of a process according to the present invention, does not enter into any appreciable reaction with either the reactants or the products.
  • a suitable inert organic solvent for use in a process according to the present invention can be selected from the group consisting of dimethylformamide, dimethyl acetamide, N-methyl pyrrolidone, sulfolane, diglyme dioxane, tetrahydrofuran and other inert organic solvents known in the art.
  • a particularly suitable inert organic solvent for use in the above process according to the present invention is dimethylformamide.
  • the above process step does not employ a scavenger base for the reaction as is taught by the prior art, but is carried out under mild conditions whereby very little by-products are produced in the reaction.
  • the work-up of the above process step is very easy and the product is filtered from the reaction mass as a hydrohalide salt of formula (I).
  • the isolation of imatinib as a hydrohalide salt is a method of purification of the product.
  • the above process is suitable for large-scale production and is economical to operate.
  • a hydrohalide salt of imatinib of formula (I), especially a hydrochloride salt of imatinib of formula (la) is converted to imatinib free base employing a process according to the present invention
  • the imatinib hydrohalide salt of formula (I) can be treated with a suitable base so as to yield imatinib free base.
  • a process according to the present invention may further comprise converting a hydrohalide salt of imatinib of formula (I), especially a hydrochloride salt of imatinib of formula (la), to a further acid addition salt of imatinib suitably by treatment of imatinib free base prepared as above, with an appropriate amount of an acid.
  • methane sulphonic acid is employed so as to yield imatinib mesylate by a process according to the present invention.
  • a process of preparing imatinib free base comprises reacting N-(2-methyl-5-aminophenyl-4-(3- pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III)
  • nHHal in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib of formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo (in particular bromo or chloro, and especially chloro), either in anhydrous or hydrated form (in particular a hydrobromide or hydrochloride, and especially a hydrochloride, typically imatinib trihydrochloride monohydrate), and further converting the resulting hydrohalide salt of imatinib of formula (I) to imatinib free base.
  • Hal represents bromo, chloro fluoro or iodo (in particular bromo or chloro, and especially chloro)
  • anhydrous or hydrated form in particular a hydrobromide or hydrochloride, and especially a hydrochloride, typically imatinib trihydrochloride monohydrate
  • the conversion comprises treatment of the imatinib hydrohalide salt of formula (I) with a suitable base so as to yield imatinib free base substantially as hereinbefore described.
  • a process of preparing imatinib free base comprises reacting N-(2-methyl-5-amino ⁇ henyl-4-(3- pyridyl)-2-pyrimidine amine of formula (II) with 4-(4-methyl-piperazino methyl)benzoyl chloride of formula (Ilia)
  • an imatinib hydrohalide salt which is a hydrochloride salt of imatinib of formula (la) where n represents 1, 2 or 3, either in anhydrous or hydrated form (typically imatinib trihydrochloride monohydrate), and further converting the resulting hydrochloride salt of imatinib of formula (la) to imatinib free base.
  • the conversion comprises treatment of the imatinib hydrochloride of formula (la) with a suitable base so as to yield imatinib free base substantially as hereinbefore described.
  • the present invention also provides a process of preparing an acid addition salt of imatinib, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III)
  • nHHal in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib of formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo (in particular bromo or chloro, and especially chloro), either in anhydrous or hydrated form (in particular a hydrobromide or hydrochloride, and especially a hydrochloride, typically imatinib trihydrochloride monohydrate), which is further converted to a further acid addition salt.
  • n 1, 2 or 3
  • Hal represents bromo, chloro fluoro or iodo (in particular bromo or chloro, and especially chloro)
  • anhydrous or hydrated form in particular a hydrobromide or hydrochloride, and especially a hydrochloride, typically imatinib trihydrochloride monohydrate
  • the conversion comprises treating a hydrohalide salt of imatinib of formula (I) either in anhydrous or hydrated form (in particular a hydrobromide or hydrochloride, and especially a hydrochloride), with a suitable base so as to yield imatimb free base substantially as hereinbefore described and subsequently treating imatinib free base with a further acid (typically methane sulphonic acid) so as to yield a further acid addition salt of imatinib (typically imatinib mesylate).
  • a hydrohalide salt of imatinib of formula (I) either in anhydrous or hydrated form (in particular a hydrobromide or hydrochloride, and especially a hydrochloride)
  • a suitable base so as to yield imatimb free base substantially as hereinbefore described
  • a further acid typically methane sulphonic acid
  • the present invention provides a process of preparing an acid addition salt of imatimb, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2- pyrimidine amine of formula (II) with 4-(4-methyl-piperazino methyl)benzoyl chloride of formula (Ilia)
  • an imatinib hydrohalide salt which is a hydrochloride salt of imatinib of formula (la) where n represents 1, 2 or 3, either in anhydrous or hydrated form (typically imatinib trihydrochloride monohydrate ⁇ which is further converted to a further acid addition salt.
  • the conversion comprises treating a hydrochloride salt of imatinib of formula (la) with a suitable base so as to yield imatinib free base substantially as hereinbefore described and subsequently treating imatinib free base with a further acid (typically methane sulphonic acid) so as to yield a further acid addition salt of imatinib (typically imatinib mesylate).
  • a further acid typically methane sulphonic acid
  • the present invention further provides an acid addition salt of imatinib prepared by a process according to the present invention substantially as hereinbefore described.
  • the acid addition salt provided by the present invention can be an imatimb hydrochloride salt of formula (la) either in anhydrous or hydrated form substantially as hereinbefore described (typically imatinib trihydrochloride monohydrate), or imatimb mesylate suitably obtained from an imatinib hydrochloride salt of formula (la) either in anhydrous or hydrated form via imatinib free base again substantially as hereinbefore described.
  • a process according to the present invention preferably further comprises preparation of N- (2-methyl-5-amino ⁇ henyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) from (2-methyl- 5-nitro ⁇ henyl)-6- ⁇ yridin-3-yl-l ,6-dihydro-pyrimidine-2-yl)-amine of formula (IV)
  • a process according to the present invention does not employ hydrogenation, but a chemical reduction process preferably with stannous chloride, which results in improved yields (65- 70%), less use of solvents and improved purity.
  • a process according to the present invention can suitably be illustrated as follows:
  • a preferred such process according to the present invention can be as follows:
  • Imatinib either as the free base or as an acid addition salt, according to the present invention, is particularly suitable for use as an antineoplastic as described in further detail in prior art document WO99/03854.
  • a pharmaceutically acceptable composition comprising an effective amount of imatinib substantially as hereinbefore described, together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
  • an effective amount means an amount of imatinib which is capable of preventing, ameliorating or eliminating a disease state, in particular rumour disease, for which administration of an antineoplastic is indicated.
  • imatinib is employed so as exhibit anti-proliferative and especially tumour inhibiting efficacy.
  • compositions are meant that the carrier, diluent or excipient must be compatible with imatinib and not be deleterious to a recipient thereof.
  • Suitable pharmaceutically acceptable compositions according to the present invention can be those suitable for topical, enteral, for example oral or rectal, or parenteral administration and may be solid or liquid.
  • Especially tablets or gelatin capsules containing imatimb substantially as hereinbefore described together with adjuvants or diluents, can be used for oral administration.
  • Solutions for injection may also be prepared according to the present invention by dissolving imatinib substantially as hereinbefore described in a solvent for injection and suitable additives conventionally used in the art may also be added.
  • imatinib mesylate can prevent the development of multidrug resistance in cancer therapy with other antitumour agents or abolishes a pre- existing resistance to other antitumour agents.
  • the present invention further provides imatinib, either as the free base or an acid addition salt substantially as hereinbefore described, for use in the manufacture of a medicament for the treatment of a disease state prevented, ameliorated or eliminated by the administration of an antineoplastic.
  • the present invention also provides a method of treating a disease state prevented, ameliorated or eliminated by the administration of an antineoplastic in an animal patient in need of such treatment, in particular tumour disease, which process comprises administering to the patient an effective amount of imatinib substantially as hereinbefore described.
  • tumours such as gliomas, ovarian tumours, prostate tumours, colon tumours and tumours ofthe lung, such as especially small cell lung carcinoma and tumours ofthe breast or other gynaecological tumours.
  • effective doses for example daily doses of about l-2500mg, typically 1-lOOOmg, more typically 5-500mg, can be administered.
  • N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine 5.0 g was suspended in dimethyl formamide (25 ml). To this was added under stirring, 4-(4-methyl-pi ⁇ erazino methyl)benzoyl chloride dihydrochloride (7.5 gms). The reaction mixture was heated under nitrogen for 15 hours at 70°C. After completion of the reaction, the reaction mixture was cooled to 20°C, stirred for 2 hours and filtered. The product obtained was dried under vacuum at 60°C for 6 hours to give the title compound (6 gms), as a pale yellow solid.
  • N- ⁇ 5-[4-(4-methyl piperazine methyl)-benzoylamido]-2-methylphenyl ⁇ -4-(3-pyridyl)-2- pyrimidine amine trihydrochloride 25 gms as prepared by Example 1 was dissolved in 100 ml of water, treated with charcoal and filtered. The pH of the clear filtrate was adjusted to about 10 with aq. ammonia. The precipitated solids were filtered and dried under vacuum to give the title compound.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

A process of preparing imatinib, either as the free base or as an acid addition salt, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III) in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatini formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo, either in anhydrous or hydrated form, which can as desired optionally be further conve either to the free base or a further acid addition salt. The present invention is also concerned with imatinib prepared according to the above process.

Description

A PROCESS OF PREPARING IMATINIB AND IMATINIB PREPARED THEREBY
The present invention is concerned with a process of preparing imatinib, either as the free base or as acid addition salts thereof, and also such imatinib free base and imatinib acid addition salts prepared by the process ofthe present invention.
Imatinib is the international non-proprietary name for N-{5-[4-(4-methyl piperazine methyl)- benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine amine.
EP 0564409 describes the preparation of imatinib and the use thereof, especially as an anti- tumour agent. In particular, Example 21 describes the preparation of imatinib free base. There is no specific preparation of an imatinib salt in EP 0564409.
The synthesis of imatinib mesylate is described in WO 99/03854. WO 99/03854 describes preparation of imatinib mesylate from imatinib free base, the preparation of the latter being referred to above mentioned EP 0564409.
The prior art synthesis of imatinib in EP 0564409 involves reduction of (2-methyl-5- nitrophenyl)-6-ρyridin-3-yl-l,6-dihydro-ρyrimidine-2-yl)-amine of formula (TV) to yield N- (2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II), followed by amidation involving N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with 4-(4-methyl-piperazino methyl)benzoyl chloride of formula (Ilia). In the prior art processes described in EP 0564409, the reduction reaction is usually carried out in presence of palladium catalyst under hydrogenation conditions. The condensation is carried out in presence of a base, such as pyridine, triethylamine or the like. The benzoyl chloride of formula (Ilia) is usually obtained as the dihydrochloride and used as such for the amidation step, and further an equivalent of hydrochloric acid is released during the reaction of N-(2- methyl-5-aminophenyl-4-(3-pyridyl)-2-ρyrimidine amine of formula (II) with the benzoyl chloride of formula (Ilia). Hence, a person skilled in the art would be expected to use a base as a scavenger for the acid released during the reaction and also to neutralize the benzoyl chloride of formula (Ilia) prior to reaction with N-(2-methyl-5-aminophenyl-4-(3-ρyridyl)-2- pyrimidine amine of formula (II).
We have found the above reaction as described in the above mentioned prior art to be unsatisfactory, whereby the reduction by hydrogenation involved large volumes of solvent, took long hours and gave a low yield (40 - 45%). The condensation reaction was also slow, gave rise to undesirable side products, and involved tedious work-up procedures. Use of a solvent such as pyridine in the last step was found to be undesirable, since it was difficult to remove residual traces thereof from the final product. Due to the additional purification steps required for removal of impurities in the process, the yield of the product was found to be low.
We have- now found a surprisingly simple process for the preparation of imatinib, which process provides an improved reduction step of (2-methyl-5-nitrophenyl)-6-pyridin-3-yl-l,6- dihydro-pyrimidine-2-yl)-amine of formula (IV) to N-(2-methyl-5-aminophenyl-4-(3- pyridyl)-2-pyrimidine amine of formula (II) and an improved amidation step of N-(2-methyl- 5-aminophenyl-4-(3-pyridyl)-2-ρyrimidine amine of formula (II) with a benzoyl halide of formula (III), which preparation overcomes the problems associated with the prior art method.
There is provided by the present invention, therefore, a process of preparing imatinib, either as the free base or as an acid addition salt, which process comprises reacting N-(2-methyl-5- aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III)
Figure imgf000005_0001
(nHHal)
Figure imgf000005_0002
in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib of formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo (in particular bromo or chloro, and especially chloro), either in anhydrous or hydrated form (in particular a hydrobromide or hydrochloride, and especially a hydrochloride), which can as desired optionally be further converted either to the free base or a further acid addition salt. A specific hydrochloride salt of imatinib of formula (I) prepared according to the present invention is imatinib trihydrochloride monohydrate.
In a preferred embodiment of the present invention, therefore, there is provided a process of preparing imatinib, either as the free base or as an acid addition salt, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with 4-(4-methyl-piperazino methyl)benzoyl chloride of formula (Ilia)
Figure imgf000006_0001
in the presence of an inert organic solvent, so as to yield an imatinib hydrohalide salt which is a hydrochloride salt of imatinib of formula (la) where n represents 1, 2 or 3, either in anhydrous or hydrated form, which can as desired optionally be further converted either to the free base or a further acid addition salt. A specific hydrochloride salt of imatinib of formula (la) prepared according to the present invention is imatinib trihydrochloride monohydrate.
There is also provided by the present invention a hydrohalide salt of imatinib of formula (I) either in anhydrous or hydrated form (nHHal)
Figure imgf000007_0001
where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo, in particular where the imatinib hydrohalide salt of formula (I) is a hydrobromide or hydrochloride salt of imatinib.
Particularly, the present invention provides a hydrochloride salt of imatinib of formula (la) either in anhydrous or hydrated form
Figure imgf000007_0002
where n represents 1, 2 or 3.
A specific hydrochloride salt of imatinib prepared according to the present invention is imatinib trihydrochloride monohydrate. The present invention also provides a hydrohalide salt of imatinib of formula (I) either in anhydrous or hydrated form obtained by a process substantially as hereinbefore described
(nHHal)
Figure imgf000008_0001
where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo, in particular where the imatinib hydrohalide salt of formula (I) is a hydrobromide or hydrochloride salt of imatinib
Particularly, the present invention provides a hydrochloride salt of imatinib of formula (la) either in anhydrous or hydrated form (especially imatinib trihydrochloride monohydrate) obtained by a process substantially as hereinbefore described
Figure imgf000008_0002
where n represents 1, 2 or 3. Suitably a hydrohalide salt of imatinib of formula (I), in particular a hydrobromide or hydrochloride salt of imatinib, and especially a hydrochloride salt of imatinib of formula (la), substantially as hereinbefore described can be employed as an intermediate in the preparation of imatinib free base or a further acid addition salt of imatinib, such as imatinib mesylate substantially as hereinafter described in greater detail.
By "inert organic solvent" is meant an organic solvent, which under the reaction conditions of a process according to the present invention, does not enter into any appreciable reaction with either the reactants or the products. A suitable inert organic solvent for use in a process according to the present invention can be selected from the group consisting of dimethylformamide, dimethyl acetamide, N-methyl pyrrolidone, sulfolane, diglyme dioxane, tetrahydrofuran and other inert organic solvents known in the art. A particularly suitable inert organic solvent for use in the above process according to the present invention is dimethylformamide.
It will be appreciated from the above that the above process step does not employ a scavenger base for the reaction as is taught by the prior art, but is carried out under mild conditions whereby very little by-products are produced in the reaction. The work-up of the above process step is very easy and the product is filtered from the reaction mass as a hydrohalide salt of formula (I). The isolation of imatinib as a hydrohalide salt is a method of purification of the product. Furthermore, the above process is suitable for large-scale production and is economical to operate.
In the case where a hydrohalide salt of imatinib of formula (I), especially a hydrochloride salt of imatinib of formula (la), is converted to imatinib free base employing a process according to the present invention, suitably the imatinib hydrohalide salt of formula (I) can be treated with a suitable base so as to yield imatinib free base. A process according to the present invention may further comprise converting a hydrohalide salt of imatinib of formula (I), especially a hydrochloride salt of imatinib of formula (la), to a further acid addition salt of imatinib suitably by treatment of imatinib free base prepared as above, with an appropriate amount of an acid. Preferably methane sulphonic acid is employed so as to yield imatinib mesylate by a process according to the present invention. In a preferred aspect of the present invention, there is provided a process of preparing imatinib free base, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3- pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III)
Figure imgf000010_0001
(nHHal)
Figure imgf000010_0002
in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib of formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo (in particular bromo or chloro, and especially chloro), either in anhydrous or hydrated form (in particular a hydrobromide or hydrochloride, and especially a hydrochloride, typically imatinib trihydrochloride monohydrate), and further converting the resulting hydrohalide salt of imatinib of formula (I) to imatinib free base. Typically the conversion comprises treatment of the imatinib hydrohalide salt of formula (I) with a suitable base so as to yield imatinib free base substantially as hereinbefore described. In a preferred aspect of the present invention, there is provided a process of preparing imatinib free base, which process comprises reacting N-(2-methyl-5-aminoρhenyl-4-(3- pyridyl)-2-pyrimidine amine of formula (II) with 4-(4-methyl-piperazino methyl)benzoyl chloride of formula (Ilia)
Figure imgf000011_0001
in the presence of an inert organic solvent, so as to yield an imatinib hydrohalide salt which is a hydrochloride salt of imatinib of formula (la) where n represents 1, 2 or 3, either in anhydrous or hydrated form (typically imatinib trihydrochloride monohydrate), and further converting the resulting hydrochloride salt of imatinib of formula (la) to imatinib free base. Typically the conversion comprises treatment of the imatinib hydrochloride of formula (la) with a suitable base so as to yield imatinib free base substantially as hereinbefore described.
There is, therefore, further provided by the present invention imatinib free base obtained by a process according to the present invention substantially as hereinbefore described. The present invention also provides a process of preparing an acid addition salt of imatinib, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III)
Figure imgf000012_0001
(nHHal)
Figure imgf000012_0002
in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib of formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo (in particular bromo or chloro, and especially chloro), either in anhydrous or hydrated form (in particular a hydrobromide or hydrochloride, and especially a hydrochloride, typically imatinib trihydrochloride monohydrate), which is further converted to a further acid addition salt. Typically the conversion comprises treating a hydrohalide salt of imatinib of formula (I) either in anhydrous or hydrated form (in particular a hydrobromide or hydrochloride, and especially a hydrochloride), with a suitable base so as to yield imatimb free base substantially as hereinbefore described and subsequently treating imatinib free base with a further acid (typically methane sulphonic acid) so as to yield a further acid addition salt of imatinib (typically imatinib mesylate). Preferably, the present invention provides a process of preparing an acid addition salt of imatimb, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2- pyrimidine amine of formula (II) with 4-(4-methyl-piperazino methyl)benzoyl chloride of formula (Ilia)
Figure imgf000013_0001
in the presence of an inert organic solvent, so as to yield an imatinib hydrohalide salt which is a hydrochloride salt of imatinib of formula (la) where n represents 1, 2 or 3, either in anhydrous or hydrated form (typically imatinib trihydrochloride monohydrate^ which is further converted to a further acid addition salt. Typically the conversion comprises treating a hydrochloride salt of imatinib of formula (la) with a suitable base so as to yield imatinib free base substantially as hereinbefore described and subsequently treating imatinib free base with a further acid (typically methane sulphonic acid) so as to yield a further acid addition salt of imatinib (typically imatinib mesylate). The present invention further provides an acid addition salt of imatinib prepared by a process according to the present invention substantially as hereinbefore described. The acid addition salt provided by the present invention can be an imatimb hydrochloride salt of formula (la) either in anhydrous or hydrated form substantially as hereinbefore described (typically imatinib trihydrochloride monohydrate), or imatimb mesylate suitably obtained from an imatinib hydrochloride salt of formula (la) either in anhydrous or hydrated form via imatinib free base again substantially as hereinbefore described.
A process according to the present invention preferably further comprises preparation of N- (2-methyl-5-aminoρhenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) from (2-methyl- 5-nitroρhenyl)-6-ρyridin-3-yl-l ,6-dihydro-pyrimidine-2-yl)-amine of formula (IV)
Figure imgf000014_0001
which process is carried out in the presence of a chemical reducing agent suitably in acidic solution, or more particularly where the chemical reducing agent comprises a metal or metal salt, and where a particularly preferred process according to the present invention is carried out in the presence of stannous chloride and hydrochloride acid.
It will be appreciated that a process according to the present invention does not employ hydrogenation, but a chemical reduction process preferably with stannous chloride, which results in improved yields (65- 70%), less use of solvents and improved purity.
A process according to the present invention can suitably be illustrated as follows:
Figure imgf000015_0001
wherein the reduction of (2-methyl-5-mtrophenyl)-6-pyridin-3-yl-l,6-dihydro-pyrimidine-2- yl)-amine of formula (IV) to yield N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) is carried out in the presence of a chemical reducing agent and the reaction of N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III) is carried out in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib of formula (I) where n and Hal are substantially as hereinbefore described, either in anhydrous or hydrated form, which can as desired optionally be further converted either to the free base or a further acid addition salt substantially as hereinbefore described.
A preferred such process according to the present invention can be as follows:
Figure imgf000016_0001
wherein the reduction of (2-methyl-5-nitrophenyl)-6-pyridin-3-yl-l,6-dihydro-pyrimidine-2- yl)-amine of formula (IV) to yield N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) is carried out in the presence of a chemical reducing agent and the reaction of N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with 4-(4-methyl-piperazino methyl)benzoyl chloride of formula (Ilia) is carried out in the presence of an inert organic solvent, so as to yield a hydrochloride salt of imatimb of formula (la) where n is substantially as hereinbefore described either in anhydrous or hydrated form, which can as desired optionally be further converted either to the free base or a further acid addition salt substantially as hereinbefore described.
Imatinib, either as the free base or as an acid addition salt, according to the present invention, is particularly suitable for use as an antineoplastic as described in further detail in prior art document WO99/03854. There is further provided by the present invention, therefore, a pharmaceutically acceptable composition comprising an effective amount of imatinib substantially as hereinbefore described, together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
The term "effective amount" as used herein means an amount of imatinib which is capable of preventing, ameliorating or eliminating a disease state, in particular rumour disease, for which administration of an antineoplastic is indicated. Typically imatinib is employed so as exhibit anti-proliferative and especially tumour inhibiting efficacy.
By "pharmaceutically acceptable composition" is meant that the carrier, diluent or excipient must be compatible with imatinib and not be deleterious to a recipient thereof. Suitable pharmaceutically acceptable compositions according to the present invention can be those suitable for topical, enteral, for example oral or rectal, or parenteral administration and may be solid or liquid. Especially tablets or gelatin capsules containing imatimb substantially as hereinbefore described together with adjuvants or diluents, can be used for oral administration. Solutions for injection may also be prepared according to the present invention by dissolving imatinib substantially as hereinbefore described in a solvent for injection and suitable additives conventionally used in the art may also be added.
It is also known from WO99/03854 that imatinib mesylate can prevent the development of multidrug resistance in cancer therapy with other antitumour agents or abolishes a pre- existing resistance to other antitumour agents. There is also provided by the present invention, therefore, a product containing imatinib, either as the free base or an acid addition salt substantially as hereinbefore described, and a further antitumour agent, for simultaneous, separate or sequential use in the treatment of tumour disease.
The present invention further provides imatinib, either as the free base or an acid addition salt substantially as hereinbefore described, for use in the manufacture of a medicament for the treatment of a disease state prevented, ameliorated or eliminated by the administration of an antineoplastic.
The present invention also provides a method of treating a disease state prevented, ameliorated or eliminated by the administration of an antineoplastic in an animal patient in need of such treatment, in particular tumour disease, which process comprises administering to the patient an effective amount of imatinib substantially as hereinbefore described. In particular such methods according to the present invention can comprise use of imatinib for treatment of tumours, such as gliomas, ovarian tumours, prostate tumours, colon tumours and tumours ofthe lung, such as especially small cell lung carcinoma and tumours ofthe breast or other gynaecological tumours. Depending on the species, age, individual condition, mode of administration and the clinical picture in question, effective doses, for example daily doses of about l-2500mg, typically 1-lOOOmg, more typically 5-500mg, can be administered.
The present invention will now be further illustrated by reference to the following Intermediates and Examples, which do not limit the scope ofthe invention in any way.
Intermediates
Preparation of (2-methyl-5-aminophenyl)-6-(pyridin-3-yl-l .6-dihydro-pyrimidine-2-yl)- amine
(2-methyl-5-nifroρhenyl)-6- yridin-3-yl-l,6-dihydro-pyrimidine-2-yl)-amine (25 gms) was dissolved in tetrahydrofuran (250 ml). To this stannous chloride (90 gms) was added and heated to 60°C for 4 hours. The reaction was cooled and filtered. The solids were dissolved in water, basified and extracted in ethylacetate. The organic layer was concentrated to give the title compound as a yellow colored solid.
Preparation of (2-methyl-5-aminophenyl -6-(pyridin-3-yl-l .6-dihydro-pyrimidine-2-yl)- amine
(2-methyl-5-nitrophenyl)-6-(pyridin-3-yl-l,6-dihydro-pyrimidine-2-yl)-amine (25 gms) was suspended in water (200 ml) and 200 ml of concentrated hydrochloric acid. To this stannous chloride (75 gms) was added and heated to 50°C for 2 hours. The reaction was cooled and neutralized with sodium hydroxide. The solids were filtered. The solids were extracted with ethyl acetate. The organic layer was concentrated to give the title compound as a yellow colored solid.
Examples
Example 1
Preparation of N-{5-[4-(4-methyl piperazine methyl)-benzoylamido]-2-methylphenyl}-4-(3- pyridyl)-2-pyrimidine amine hydrochloride (Imatinib trihydrochloride monohydrate)
N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine 5.0 g was suspended in dimethyl formamide (25 ml). To this was added under stirring, 4-(4-methyl-piρerazino methyl)benzoyl chloride dihydrochloride (7.5 gms). The reaction mixture was heated under nitrogen for 15 hours at 70°C. After completion of the reaction, the reaction mixture was cooled to 20°C, stirred for 2 hours and filtered. The product obtained was dried under vacuum at 60°C for 6 hours to give the title compound (6 gms), as a pale yellow solid.
Example 2
N-(5-[4-(4-methylpiperazinemethylVberizoylamido]-2-metfaylphenyl}-4-(3-pyridylV2- pyrimidine amine free base (Imatinib free base)
N- {5-[4-(4-methyl piperazine methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2- pyrimidine amine trihydrochloride (25 gms) as prepared by Example 1 was dissolved in 100 ml of water, treated with charcoal and filtered. The pH of the clear filtrate was adjusted to about 10 with aq. ammonia. The precipitated solids were filtered and dried under vacuum to give the title compound.
Example 3
N- {5-[4-(4-methyl piperazine methylVbenzoylamido1-2-methylphenyl}-4-(3-ρyridyl)-2- pyrimidine amine mesylate (Imatinib mesylate)
N- {5-[4-(4-methyl piperazine methyl)-benzoylamido]-2-methylρhenyl}-4-(3-pyridyl)-2- pyrimidine amine free base (50 gms) was suspended in isopropanol (500 ml). Methane sulphonic acid (9.85 gms) was added and the reaction mixture was refluxed for 2 hours. The reaction mixture was concentrated to about 100 ml volume, cooled and the product isolated to the title compound as the mesylate salt. (55 gms).

Claims

1. A process of preparing imatinib, either as the free base or as an acid addition salt, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III)
Figure imgf000021_0001
(nHHal)
Figure imgf000021_0002
in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib of formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro, fluoro or iodo, either in anhydrous or hydrated form which can as desired optionally be further converted either to the free base or a further acid addition salt.
2. A process according to claim 1, wherein Hal represents bromo or chloro, and whereby the imatinib hydrohalide salt prepared is a hydrobromide or hydrochloride salt of imatimb.
3. A process according to claim 2, wherein Hal represents chloro, and whereby the imatinib hydrohalide salt prepared is a hydrochloride salt of imatinib.
4. A process according to claim 3, wherein the imatinib hydrohalide salt prepared is imatinib trihydrochloride monohydrate.
5. A process of preparing imatinib, either as the free base or as an acid addition salt, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with 4-(4-methyl-piperazino methyl)benzoyl chloride of formula (Ilia)
Figure imgf000022_0001
in the presence of an inert organic solvent, so as to yield an imatinib hydrohalide salt which is a hydrochloride salt of imatimb of formula (la) where n represents 1, 2 or 3, either in anhydrous or hydrated form, which can as desired optionally be further converted either to the free base or a further acid addition salt.
6. A process according to claim 5, wherein the imatinib hydrohalide salt prepared is imatinib trihydrochloride monohydrate.
7. A process according to any of claims 1 to 6, wherein said inert organic solvent is selected from the group consisting of dimethylformamide, dimethyl acetamide, N-methyl pyrrolidone, sulfolane, diglyme dioxane and tetrahydrofuran.
8. A process according to claim 7, wherein said inert organic solvent comprises dimethylformamide.
9. A process according to any of claims 1 to 8, wherein the imatinib hydrohalide salt is treated with a base so as to yield imatinib free base.
10. A process according to claim 9, wherein said imatimb free base is treated with an acid so as to yield a further acid addition salt of imatinib.
11. A process according to claim 10, wherein said imatinib free base is treated with methane sulphonic acid so as to yield imatinib mesylate.
12. A process of preparing imatinib free base, which process comprises reacting N-(2- methyl-5-aminophenyl-4-(3-pyridyl)-2-ρyrimidine amine of formula (II) with a 4-(4-methyl- piperazino methyl)benzoyl halide of formula (III)
Figure imgf000024_0001
(nHHal)
Figure imgf000024_0002
in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib of formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo, either in anhydrous or hydrated form and further converting the resulting hydrohalide salt of imatinib to imatinib free base.
13. A process according to claim 12, wherein Hal represents bromo or chloro, and whereby the imatinib hydrohalide salt prepared is a hydrobromide or hydrochloride salt of imatinib.
14. A process according to claim 13, wherein Hal represents chloro, and whereby the imatinib hydrohalide salt prepared is a hydrochloride salt of imatinib.
15. A process according to claim 14, wherein the imatinib hydrohalide salt prepared is imatinib trihydrochloride monohydrate.
16. A process of preparing imatinib free base, which process comprises reacting N-(2- methyl-5-armnoρhenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with 4-(4-methyl- piperazino methyι)benzoyl chloride of formula (Ilia)
Figure imgf000025_0001
in the presence of an inert organic solvent, so as to yield a hydrochloride salt of imatinib of formula (la) where n represents 1, 2, or 3, and further converting the resulting hydrochloride salt of imatinib to imatinib free base.
17. A process according to any of claims 12 to 16, which comprises treating the imatinib hydrohalide salt prepared with a base so as to yield imatinib free base.
18. A process of preparing an acid addition salt of imatinib, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III)
Figure imgf000026_0001
(nHHal)
Figure imgf000026_0002
in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib of formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo, either in anhydrous or hydrated form which is further converted to a further acid addition salt.
19. A process according to claim 18, wherein Hal represents bromo or chloro, and whereby the imatinib hydrohalide salt prepared is a hydrobromide or hydrochloride salt of imatinib.
20. A process according to claim 19, wherein Hal represents chloro, and whereby the imatinib hydrohalide salt prepared is a hydrochloride salt of imatinib.
21. A process according to claim 20, wherein whereby the imatinib hydrohalide salt prepared is imatinib trihydrochloride monohydrate.
22. A process of preparing an acid addition salt of imatimb, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrirnidine amine of formula (II) with 4-(4-methyl-piperazino methyl)benzoyl chloride of formula (Ilia)
Figure imgf000027_0001
in the presence of an inert organic solvent, so as to yield an imatinib hydrohalide salt which is a hydrochloride salt of imatinib of formula (la) where n represents 1, 2 or 3, either in anhydrous or hydrated form, which is further converted to a further acid addition salt.
23. A process according to any of claims 18 to 22, which comprises treating the imatinib hydrohalide salt with a base so as to yield imatinib free base and subsequently treating imatinib free base with an acid.
24. A process according to claim 23, which comprises treating imatinib free base with methane sulphonic acid so as to yield imatinib mesylate.
25. A process according to any of claims 1 to 24, which further comprises preparing N- (2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) from (2-methyl- 5-nitrophenyl)-6-pyridin-3-yl-lJ6-dihydro-pyrimidine-2-yl)-amine of formula (IV)
Figure imgf000028_0001
which process is carried out in the presence of a chemical reducing agent.
26. A process according to claim 25, wherein the chemical reducing agent comprises a metal or metal salt.
27. A process according to claim 26, which is carried out in the presence of stannous chloride and hydrochloride acid.
28. A process illustrated by the following scheme:
Figure imgf000029_0001
wherein the reduction of (2-methyl-5-nitrophenyl)-6-pyridin-3-yl-l,6-dihydro-ρyrimidine-2- yl)-amine of formula (TV) to yield N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) is carried out in the presence of a chemical reducing agent and the reaction of N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III) is carried out in the presence of an inert organic solvent, so as to yield a hydrohalide salt of imatinib of formula (I) where n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo, either in anhydrous or hydrated form, which can as desired optionally be further converted either to the free base or a further acid addition salt.
29. A process according to claim 28, wherein Hal represents bromo or chloro, and whereby the imatinib hydrohalide salt prepared is a hydrobromide or hydrochloride salt of imatinib.
30. A process according to claim 29, wherein Hal represents chloro, and whereby the imatinib hydrohalide salt prepared is a hydrochloride salt of imatinib.
31. A process according to claim 30, whereby the imatinib hydrohalide salt prepared is imatinib trihydrochloride monohydrate.
32. A process illustrated by the following scheme:
Figure imgf000031_0001
wherein the reduction of (2-methyl-5-nitrophenyl)-6-pyridin-3-yl-l,6-dihydro-pyrimidine-2- yl)-amine of formula (IV) to yield N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) is carried out in the presence of a chemical reducing agent and the reaction of N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with 4-(4-methyl-piperazino methyl)benzoyl chloride of formula (Ilia) is carried out in the presence of an inert organic solvent, so as to yield a hydrochloride salt of imatinib of formula (la) where n represents 1, 2 or 3 either in anhydrous or hydrated form, which can as desired optionally be further converted either to the free base or a further acid addition salt.
33. A hydrohalide salt of imatinib of formula (I) either in anhydrous or hydrated form:
(nHHal)
Figure imgf000032_0001
wherein n represents 1, 2 or 3 and Hal represents bromo, chloro fluoro or iodo.
34. A hydrochloride salt of imatinib of formula (la) either in anhydrous or hydrated form:
Figure imgf000032_0002
where n represents 1, 2 or 3.
35. Imatinib trihydrochloride monohydrate.
36. An acid addition salt of imatinib prepared by a process according to any of claims 1 to
32.
37. A hydrochloride salt of imatinib of formula (la)
Figure imgf000033_0001
where n represents 1, 2 or 3, either in anhydrous or hydrated form, prepared by a process according to any of claims 1 to 32.
38. Imatinib trihydrochloride monohydrate prepared by a process according to any of claims 1 to 32.
39. Imatinib mesylate prepared by a process according to any of claims 1 to 32.
40. Imatinib free base prepared by a process according to any of claims 1 to 32.
41. A pharmaceutically acceptable composition comprising an effective amount of imatinib according to any of claims 33 to 40, together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
42. A product containing imatinib according to any of claims 33 to 40 and a further antitumour agent, for simultaneous, separate or sequential use in the treatment of tumour disease
43. Imatinib according to any of claims 33 to 40, for use in the manufacture of a medicament for the treatment of a disease state prevented, ameliorated or eliminated by the administration of an antineoplastic.
44. A method of treating a disease state prevented, ameliorated or eliminated by the administration of an antineoplastic in an animal patient in need of such treatment, in particular tumour disease, which process comprises administering to the patient an effective amount of imatinib according to any of claims 33 to 40.
PCT/GB2004/000018 2003-02-18 2004-01-08 A process of preparing imatinib Ceased WO2004074502A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0407672-9A BRPI0407672A (en) 2003-02-18 2004-01-08 processes for preparing imatinib and an acid addition salt thereof, imatinib acid addition salts, pharmaceutically acceptable composition thereof, imatinib and use thereof
NZ542040A NZ542040A (en) 2003-02-18 2004-01-08 A process of preparing imatinib
KR1020057015166A KR101086845B1 (en) 2003-02-18 2004-01-08 How to prepare imatinib
JP2006502181A JP5064024B2 (en) 2003-02-18 2004-01-08 Method for producing imatinib and imatinib produced by the method
AU2004213616A AU2004213616B2 (en) 2003-02-18 2004-01-08 A process of preparing imatinib
EP04700728A EP1599462B1 (en) 2003-02-18 2004-01-08 Process of preparing imatinib
CA2516370A CA2516370C (en) 2003-02-18 2004-01-08 A process of preparing imatinib and imatinib prepared thereby
US10/546,193 US7638627B2 (en) 2003-02-18 2004-01-08 Process of preparing imatinib and imatinib prepared thereby

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0303730.6 2003-02-18
GB0303730A GB2398565A (en) 2003-02-18 2003-02-18 Imatinib preparation and salts

Publications (2)

Publication Number Publication Date
WO2004074502A2 true WO2004074502A2 (en) 2004-09-02
WO2004074502A3 WO2004074502A3 (en) 2004-10-28

Family

ID=9953245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/000018 Ceased WO2004074502A2 (en) 2003-02-18 2004-01-08 A process of preparing imatinib

Country Status (12)

Country Link
US (1) US7638627B2 (en)
EP (1) EP1599462B1 (en)
JP (1) JP5064024B2 (en)
KR (1) KR101086845B1 (en)
AU (1) AU2004213616B2 (en)
BR (1) BRPI0407672A (en)
CA (1) CA2516370C (en)
GB (1) GB2398565A (en)
NZ (1) NZ542040A (en)
PL (1) PL378128A1 (en)
RU (1) RU2415849C2 (en)
WO (1) WO2004074502A2 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005075454A2 (en) 2004-02-04 2005-08-18 Novartis Ag SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
JP2006527230A (en) * 2003-06-13 2006-11-30 ノバルティス アクチエンゲゼルシャフト 2-Aminopyrimidine derivatives as RAF kinase inhibitors
JP2007302658A (en) * 2006-04-27 2007-11-22 Ivax Pharmaceuticals Spolecnost Sro POLYMORPHIC FORM AND NEW CRYSTAL FORM AND AMORPHOUS FORM OF IMATINIB MESYLATE, AND METHOD FOR PREPARING FORMalpha
WO2008051597A1 (en) * 2006-10-26 2008-05-02 Sicor Inc. Process for the preparation of imatinib
EP1988089A1 (en) 2006-10-26 2008-11-05 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
WO2008135980A1 (en) * 2007-05-02 2008-11-13 Chemagis Ltd. Imatinib production process
US7507821B2 (en) 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
WO2009080366A1 (en) * 2007-12-22 2009-07-02 Synthon B.V. A process of making imatinib
WO2010133976A2 (en) 2009-05-22 2010-11-25 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
WO2011070588A1 (en) 2009-12-10 2011-06-16 Arch Pharmalabs Limited Process for the preparation of imatinib and salts thereof
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
US8048883B2 (en) 2004-02-11 2011-11-01 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
WO2012026897A1 (en) * 2010-08-23 2012-03-01 MUSTAFA NEVZAT iLAÇ SANAYU A.Ş. A process for the preparation of imatinib base
CN102382100A (en) * 2011-03-09 2012-03-21 上海昕盛医药科技有限公司 Preparation method of imatinib
WO2012087255A2 (en) 2010-12-20 2012-06-28 Mahmut Bilgic Pharmaceutical formulations
WO2012131711A1 (en) * 2011-03-31 2012-10-04 Ind-Swift Laboratories Limited Improved process for preparation of imatinib and its mesylate salt
WO2013035102A1 (en) 2011-09-05 2013-03-14 Natco Pharma Limited Processes for the preparation of imatinib base and intermediates thereof
US8414918B2 (en) 2007-09-25 2013-04-09 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
RU2483065C2 (en) * 2005-07-20 2013-05-27 Новартис Аг 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)benzamide salts
CN103910711A (en) * 2014-03-24 2014-07-09 福建天泉药业股份有限公司 Imatinib free alkali crystal form and preparation method thereof
WO2017129624A1 (en) 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
CN119490479A (en) * 2024-11-15 2025-02-21 广州科锐特药业有限公司 A preparation method of imatinib mesylate

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
US8269003B2 (en) 2004-09-02 2012-09-18 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
KR20070073813A (en) * 2004-09-27 2007-07-10 아스트라제네카 아베 Combination Therapy of Cancer Including AHDD2171 and Imatinib
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
CN102861338A (en) * 2006-04-05 2013-01-09 诺瓦提斯公司 Combinations of comprising a bcr-abl, c-kit and pdgf-r tyrosine kinase inhibitor used for treating cancer
US20060223816A1 (en) * 2006-05-08 2006-10-05 Chemagis Ltd. Imatinib mesylate alpha form and production process therefor
WO2008024829A2 (en) * 2006-08-23 2008-02-28 Board Of Regents, The University Of Texas System Radiohaloimatinibs and methods of their synthesis and use in pet imaging of cancers
BRPI0715634A2 (en) * 2006-09-01 2013-07-02 Teva Pharma imatinib compositions
RU2329260C1 (en) * 2007-02-20 2008-07-20 Юрий Иосифович Копырин Method of obtaining 2-anilinopyrimidines or their salts (options)
DK2305263T3 (en) * 2007-06-07 2012-10-22 Novartis Ag Stabilized amorphous forms of imatinib mesylate
WO2009060463A1 (en) * 2007-11-05 2009-05-14 Natco Pharma Limited An environmentally friendly process for the preparation of imatinib base
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
US20130060030A1 (en) * 2010-03-15 2013-03-07 Natco Pharma Limited Process for the preparation of highly pure crystalline imatinib base
WO2011130918A1 (en) 2010-04-23 2011-10-27 上海百灵医药科技有限公司 Process for synthesizing imatinib
CN102250063B (en) * 2010-05-19 2014-10-22 江苏豪森药业股份有限公司 Crystal form of imatinib mesylate and preparation method thereof
CN101899035B (en) * 2010-09-03 2012-09-05 天津市炜杰科技有限公司 Preparation method of high-purity imatinib
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
WO2012070062A2 (en) * 2010-11-26 2012-05-31 Hetero Research Foundation Novel polymorph of nilotinib hydrochloride
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
CN102070605B (en) * 2011-01-30 2013-03-13 南京卡文迪许生物工程技术有限公司 Imatinib mesylate polymorph and pharmaceutical composition
KR101286780B1 (en) * 2011-02-01 2013-07-17 에스티팜 주식회사 A bicarbonate salt and a method of preparing imatinib and salt using the same
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CN102260242B (en) * 2011-05-27 2014-08-06 南京卡文迪许生物工程技术有限公司 Polymouphous substance of imatinib mesylate and medicinal composition thereof
CN102816145B (en) * 2011-06-11 2014-09-03 南京卡文迪许生物工程技术有限公司 Methanesulfonic acid imatinib polymorphic substance and medical combination thereof
JP6096205B2 (en) 2011-11-01 2017-03-15 モッドジーン リミテッド ライアビリティ カンパニーＭｏｄｇｅｎｅ，Ｌｌｃ Use of imatinib derivatives exhibiting reduced protein kinase inhibition
CN102659762A (en) * 2012-05-24 2012-09-12 石药集团中奇制药技术（石家庄）有限公司 Crystal form of imatinib mesylate and preparation method thereof
WO2014041551A1 (en) 2012-09-14 2014-03-20 Natco Pharma Limited Formulation comprising imatinib as oral solution
EP2749557A1 (en) 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Process for preparation of alpha polymorph of imatinib mesylate from IPA and THF solvate forms of imatinib mesylate
CN104163812A (en) * 2013-05-17 2014-11-26 浙江九洲药业股份有限公司 Amorphous imatinib mesylate and preparation method thereof
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
JP6799201B2 (en) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． Aerosol Tyrosine Kinase Inhibitor Compounds and Their Use
CN104974133B (en) * 2014-04-09 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 A kind of Crystal form of imatinib mesylate and preparation method thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
WO2020232238A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Inhalable formulations for kinase inhibition
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
SG10201909596RA (en) * 2019-10-14 2021-05-28 Esco Aster Pte Ltd Synthesis of Tyrosine Kinase Inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (en) 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidin derivatives and process for their preparation
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564409A1 (en) 1992-04-03 1993-10-06 Ciba-Geigy Ag Pyrimidin derivatives and process for their preparation
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527230A (en) * 2003-06-13 2006-11-30 ノバルティス アクチエンゲゼルシャフト 2-Aminopyrimidine derivatives as RAF kinase inhibitors
US8513256B2 (en) 2004-02-04 2013-08-20 Novartis Ag Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
JP2007520518A (en) * 2004-02-04 2007-07-26 ノバルティス アクチエンゲゼルシャフト Salt form of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl] -benzamide
JP4937760B2 (en) * 2004-02-04 2012-05-23 ノバルティス アーゲー Salt form of 4- (4-methylpiperazin-1-ylmethyl) -N- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl] -benzamide
WO2005075454A3 (en) * 2004-02-04 2006-07-27 Novartis Ag SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE
WO2005075454A2 (en) 2004-02-04 2005-08-18 Novartis Ag SALT FORMS OF 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE
EP1720853B1 (en) * 2004-02-11 2015-12-30 Natco Pharma Limited Novel polymorphic form of imatinib mesylate and a process for its preparation
US8048883B2 (en) 2004-02-11 2011-11-01 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
WO2006054314A1 (en) * 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US7507821B2 (en) 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
US9163005B2 (en) 2005-07-20 2015-10-20 Novartis Ag Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
RU2509767C1 (en) * 2005-07-20 2014-03-20 Новартис Аг 4-methyl-n-[3-4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)benzamide salts
RU2483065C2 (en) * 2005-07-20 2013-05-27 Новартис Аг 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)benzamide salts
RU2605551C2 (en) * 2005-07-20 2016-12-20 Новартис Аг Salts of 4-methyl-n-[3-(4-methylimidazole-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridine-3-ylpyrimidine-2-ylamino)benzamide
US7977348B2 (en) 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US8067421B2 (en) 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
JP2007302658A (en) * 2006-04-27 2007-11-22 Ivax Pharmaceuticals Spolecnost Sro POLYMORPHIC FORM AND NEW CRYSTAL FORM AND AMORPHOUS FORM OF IMATINIB MESYLATE, AND METHOD FOR PREPARING FORMalpha
EP2009008A1 (en) 2006-10-26 2008-12-31 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
WO2008051597A1 (en) * 2006-10-26 2008-05-02 Sicor Inc. Process for the preparation of imatinib
WO2008057291A3 (en) * 2006-10-26 2008-07-03 Sicor Inc Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof
EP1988089A1 (en) 2006-10-26 2008-11-05 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008135980A1 (en) * 2007-05-02 2008-11-13 Chemagis Ltd. Imatinib production process
US8414918B2 (en) 2007-09-25 2013-04-09 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
WO2009065910A3 (en) * 2007-11-21 2009-12-30 Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
EP2062885A1 (en) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Acid addition salts of imatinib and formulations comprising the same
WO2009080366A1 (en) * 2007-12-22 2009-07-02 Synthon B.V. A process of making imatinib
WO2010133976A2 (en) 2009-05-22 2010-11-25 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
WO2011070588A1 (en) 2009-12-10 2011-06-16 Arch Pharmalabs Limited Process for the preparation of imatinib and salts thereof
WO2011095835A1 (en) 2010-02-02 2011-08-11 Actavis Group Ptc Ehf Highly pure imatinib or a pharmaceutically acceptable salt thereof
WO2011157450A1 (en) 2010-06-18 2011-12-22 Krka, D. D., Novo Mesto New polymorphic form of imatinib base and preparation of salts thereof
US8252926B2 (en) 2010-08-23 2012-08-28 Mustafa Nevzat llaç Sanayii A.S. Process for the preparation of imatinib base
WO2012026897A1 (en) * 2010-08-23 2012-03-01 MUSTAFA NEVZAT iLAÇ SANAYU A.Ş. A process for the preparation of imatinib base
WO2012087255A2 (en) 2010-12-20 2012-06-28 Mahmut Bilgic Pharmaceutical formulations
CN102382100A (en) * 2011-03-09 2012-03-21 上海昕盛医药科技有限公司 Preparation method of imatinib
WO2012131711A1 (en) * 2011-03-31 2012-10-04 Ind-Swift Laboratories Limited Improved process for preparation of imatinib and its mesylate salt
US8912325B2 (en) 2011-03-31 2014-12-16 Ind-Swift Laboratories Limited Process for preparation of imatinib and its mesylate salt
WO2013035102A1 (en) 2011-09-05 2013-03-14 Natco Pharma Limited Processes for the preparation of imatinib base and intermediates thereof
CN103910711A (en) * 2014-03-24 2014-07-09 福建天泉药业股份有限公司 Imatinib free alkali crystal form and preparation method thereof
WO2017129624A1 (en) 2016-01-25 2017-08-03 Krka, D.D., Novo Mesto Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
CN119490479A (en) * 2024-11-15 2025-02-21 广州科锐特药业有限公司 A preparation method of imatinib mesylate
CN119490479B (en) * 2024-11-15 2025-08-12 广州科锐特药业有限公司 Preparation method of imatinib mesylate

Also Published As

Publication number Publication date
PL378128A1 (en) 2006-03-06
US7638627B2 (en) 2009-12-29
AU2004213616A1 (en) 2004-09-02
KR101086845B1 (en) 2011-11-24
JP2006518360A (en) 2006-08-10
GB0303730D0 (en) 2003-03-26
RU2415849C2 (en) 2011-04-10
US20060173182A1 (en) 2006-08-03
EP1599462A2 (en) 2005-11-30
AU2004213616B2 (en) 2011-05-26
AU2004213616A2 (en) 2004-09-02
RU2005129100A (en) 2006-06-10
NZ542040A (en) 2009-02-28
BRPI0407672A (en) 2006-03-01
GB2398565A (en) 2004-08-25
EP1599462B1 (en) 2013-03-27
KR20050108358A (en) 2005-11-16
WO2004074502A3 (en) 2004-10-28
JP5064024B2 (en) 2012-10-31
CA2516370A1 (en) 2004-09-02
CA2516370C (en) 2012-08-21

Similar Documents

Publication Publication Date Title
EP1599462B1 (en) Process of preparing imatinib
JP3447292B2 (en) Imidazopyridines and their use for the treatment of gastrointestinal diseases
US8518936B2 (en) Method for preparing acid addition salts of polyacidic basic compounds
JP2010526056A (en) Method for producing imatinib
MXPA04009384A (en) Lansoprazole polymorphs and processes for preparation thereof.
JP2515434B2 (en) 2-Aminopyrimidine-4-carboxamide derivative, method for producing the same and medicament containing the same
JP6644685B2 (en) Preparation of pomalidomide and improved method for its purification
JP3323420B2 (en) Benzimidazole derivatives
CN110804059B (en) Carbamate compounds, pharmaceutical compositions and their applications
TWI464150B (en) Quinoxaline derivatives and their use for treating benign and malignant tumour disorders
WO2017049992A1 (en) Egfr kinase inhibitor and preparation method and use thereof
JPWO2009041559A1 (en) Indazole acrylic acid amide compound
US11014943B2 (en) Azetidine derivative
JPH045289A (en) Amide compound
JP2004511486A (en) Morphinoid derivatives as delta-opioid agonists and antagonists
WO2008142623A2 (en) Tumor necrosis factor - alpha inhibitors
JP3285421B2 (en) 2-Amino-N-[[[4- (aminocarbonyl) pyrimidin-2-yl] amino] alkyl] pyrimidine-4-carboxamide derivative, its production and application to medicine
JP2009073743A (en) Novel fused cyclic pyrimidine compound or salt thereof and pharmaceutical composition thereof
WO2013138200A1 (en) Green chemistry synthesis of the malaria drug amodiaquine and analogs thereof
JP2011102241A (en) Novel 1-aminocarbonylpiperidine derivative
CN114276328B (en) Compound as small molecule immunosuppressant, preparation method and application thereof
CN121735909A (en) Multivalent molecular gum compound, and preparation and application thereof
JP2582402B2 (en) Isoxazolin-3-one derivatives and uses thereof
HUT69711A (en) 2-amino-pyrazine-5-carboxamide derivatives process for producing them and pharmaceutical composition containing them
JP2007503376A (en) Novel N-substituted indolyl-3-glyoxylic acid amides, their use as pharmaceuticals and methods for their production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2516370

Country of ref document: CA

Ref document number: 2006502181

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057015166

Country of ref document: KR

Ref document number: 378128

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 950/MUMNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004213616

Country of ref document: AU

Ref document number: 542040

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2004213616

Country of ref document: AU

Date of ref document: 20040108

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004213616

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004700728

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005129100

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006173182

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10546193

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020057015166

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004700728

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0407672

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10546193

Country of ref document: US